|
|
Study on Induction of Human Muse Cells into Neural Precursor Cells in vitro |
1 Department of Histology and Embryology, School of Medicine, Nantong University, Nantong 226001, Jiangsu, China
2 Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China |
|
|
Abstract The work explored approaches of inducing Muse cells derived from the adult bone marrow into neural precursor cells in vitro. Human bone marrow stromal cells (hBMSCs) were separated and cultured from the healthy adult bone marrow. Then Muse cells were collected using the flow cytometry sorting. In order to observe the characteristics of the pluripotent stem cells, Muse cells were analyzed using immunocytochemical staining and qPCR assay. Afterward, neural inducing culture media was used to induce Muse cells into neural precursor cells (Muse-NPCs). The immunocytochemical staining and qPCR assay were used to observe the expression of the markers specific for the neural stem cell in Muse cells. Muse cells accounting for about 0.58% of hBMSCs were obtained that expressing the markers of the pluripotent stem cells: SSEA-3, Nanog and Oct4. Muse cells also showed significantly higher levels of mRNA of these markers comparing to hBMSCs (P<0.01). The induced Muse-NPCs expressed the markers of neural stem cells including Nestin and βIII-tubulin. Additionally, the levels of mRNA of these markers in Muse-NPCs was significantly higher than those in hBMSCs and Muse cells (P<0.01). In conclusion, Muse cells were successfully separated from adult bone marrow and then induced into Muse-NPCs in vitro, providing a new type of seed cells for the cell therapies in the nervous system.
|
|
|
|
|
[1]McKinley W, Santos K, Meade M, et al. Incidence and outcomes of spinal cord injury clinical syndromes [J]. J Spinal Cord Med, 2007, 30(3):215-224.
[2]Tetzlaff W, Okon EB, KarimiAbdolrezaee S, et al. A systematic review of cellular transplantation therapies for spinal cord injury [J]. Neurotrauma, 2011, 28(8):1611-1682.
[3]Sayer FT, Kronvall E, Nilsson OG. Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature [J]. Spine J, 2006, 6(3):335-343.
[4]Wright KT, El Masri W, Osman A, et al. Concise review: Bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications [J]. Stem Cells, 2011, 29(2):169-178.
[5]Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors [J]. Cell, 2007, 131(5):861-872.
[6]Yang JR, Liao CH, Pang CY, et al. Transplantation of porcine embryonic stem cells and their derived neuronal progenitors in a spinal cord injury rat model [J]. Cytotherapy, 2013, 15(2):201-208.
[7]Bilic J, IzpisuaBelmonte JC. Concise review: Induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart? [J] Stem Cells, 2012, 30(1):33-41.[8]Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation [J]. Nature, 2009, 460(7251):49-52.
[9]Abollo\|Jimenez F, Jimenez R, Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol, 2010, 20(2):98-106.
[10]Zhang Duo, He Xijing. A metaanalysis of the motion function through the therapy of spinal cord injury with intravenous transplantation of bone marrow mesenchymal stem cells in rats [J]. PLoS ONE, 2014, 9(4):e93487.
[11]Bao Xinjie, Feng Ming, Wei Junji, et al. Transplantation of Flk-1+ human bone marrowderived mesenchymal stem cells promotes angiogenesis and neurogenesis after cerebral ischemia in rats [J]. Eur J Neurosci, 2011, 34(1):87-98.
[12]Kuroda Y, Kitada M, Nishikawa K, et al. Unique multipotent cells in adult human mesenchymal cell populations [J]. Proc Natl Acad Sci USA, 2010, 107(19):8639-8643.
[13]Chen Xue, Yang Yang, Yao Jian, et al. Bone marrow stromal cellsloaded chitosan conduits promote repair of complete transection injury in rat spinal cord [J]. J Mater Sci Mater Med, 2011, 22(10):2347-2356.
[14]Kitada M, Wakao S, Dezawa M. Muse cells and induced pluripotent stem cell: implication of the elite model [J]. Cell Mol Life Sci, 2012, 69(22):3739-3750.
[15]Wakao S, Kitada M, Kuroda Y, et al. Multilineagedifferentiating stressenduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts [J]. Proc Natl Acad Sci USA, 2011, 108(24):9875-9880.
[16]Kuroda Y, Wakao S, Kitada M, et al. Isolation, culture and evaluation of multilineagedifferentiating stressenduring (Muse) cells [J]. Nat Protoc, 2013, 8(7):1391-1415.
[17]Ogura F, Wakao S, Kuroda Y, et al. Human adipose tissue possesses a unique population of pluripotent stem cells with nontumorigenic and low telomerase activities: potential implications in regenerative medicine [J]. Stem Cells Dev, 2014, 23(7):717-728.
[18]Simerman AA, Dumesic DA, Chazenbalk GD. Pluripotent muse cells derived from human adipose tissue: a new perspective on regenerative medicine and cell therapy [J]. Clin Transl Med, 2014, 3(1):1-8.
[19]Wakao S, Akashi H, Kushida Y, et al. Muse cells, newly found nontumorigenic pluripotent stem cells, reside in human mesenchymal tissues [J]. Pathol Int, 2014, 64(1):1-9.[20]Kuroda Y, Dezawa M. Mesenchymal stem cells and their subpopulation, pluripotent muse cells, in basic research and regenerative medicine[J]. Anat Rec, 2014, 297(1):98-110.
[21]Yamauchi T, Kuroda Y, Morita T, et al. Therapeutic effects of human multilineagedifferentiating stress enduring (MUSE) cell transplantation into infarct brain of mice [J]. PLoS ONE, 2015, 10(3):e0116009.
[22]Carpenter MK, Cui Xia, Hu Zhongyi, et al. In vitro expansion of a multipotent population of human neural progenitor cells [J]. Exp Neurol, 1999, 158(2):265-278.
|
|
|
|